UP-TO-DATE MANAGEMENT OF LIVER DISEASE AND COMPLICATIONS IN CYSTIC FIBROSIS AND TRANSITION OF ADOLESCENTS FROM PEDIATRIC TO ADULT CARE
Abstract
Cystic fibrosis (CF) is the most common autosomal recessive lethal hereditary disorder among whites. Survival of patients with CF has progressively improved over the last four decades.
As life expectancy has been greatly extended, complications like osteopenia and CF-related diabetes mellitus (CFRDM) occur. In our article, a new management of these two complications is described.
Gastrointestinal tract, exocrine pancreas and liver are also affected in CF.
Maintaining good nutrition while treating pancreatic insufficiency, treating gastroesophageal reflux disease and treating liver disease are very important issues in the treatment gastrointestinal tract disease in CF.
As the CF patient population median survival increases, a growing number of adolescents require care in the adult health care system which must be capable of responding appropriately to their needs.
We present a model of transition from paediatric to adult medical care in our CF center.
Downloads
References
O'Riordan SMP, Dattani MT, Hindmarsh PC. Cystic fibrosis-related diabetes in childhood. Horm Res 2010;73:15-24.
Adler AI, Shine BSF, Chamnan P, Haworth CS, Bilton D. Genetic determinants and epidemiology of cystic fibrosis-related diabetes. Diabetes Care 2008; 31:1789-94.
Cucinotta D, De Luca F, Scoglio R, Lombardo F, Sferlazzas C, Di Benedetto A, et al. Factors affecting diabetes mellitus onset in cystic fibrosis: evidence from a 10-year follow-up study. Acta Paediatr 1999; 88: 389-93.
Blackman SM, Commander CW, Watson C, et al. Genetic modifiers of cystic fibrosis-related diabetes. Diabetes 2013;62: 3627-35.
Pincikova T, Nilson K, Moen IE, Fluge G, Hollsing A, Knudsen PK, et al. Vitamin D deficiency as a risk factor for cystic fibrosis-related diabetes in the Cystic Fibrosis Nutritional Study. Diabetologia 2011; 54: 3007-15.
Ntimbane T, Compte B, Mailhot G, Berthiaume Y, Poitout V, Prentki M, et al. Cystic-fibrosis-related diabetes: From CFTR Dysfunction to Oxidative Stress. Clin Biochem Rev 2008; 30:153-72.
Bismuth E, Laborde K, Taupin P, Velho G, Ribault V, Jennane F, et al. Glucose tolerance and insulin secretion, morbidity, and death in patients with cystic fibrosis. J Pediatr 2008; 152: 540-5.
Moran A, Doherty L, Wang X, Thomas W. Abnormal glucose metabolism in cystic fibrosis. J Pediatr 1998;133:10-7.
Hunt WR, Zughaier SM, Guentert DE, et al. Hyperglycemia impedes lung bacterial clearance in a murine model of cystic fibrosis-related diabetes. Am J Physiol Lung Cell Mol Physiol 2014; 306: L43-9.
O'Riordan SMP, Robinson PD, Donaghue KC, Moran A & ISPAD Clinical Practice Consensus Guidelines 2008. Management of cystic fibrosis-related diabetes. Pediatric Diabetes 2008; 9: 338-44.
O' Riordan SMP, Hindmarsh P, Hill NR, Matthews DR, George S, Greally P, et al. Validation of continuous glucose monitoring in children and adolescents with cystic fibrosis. Diabetes Care 2009; 32: 1020-22.
Schiaffini R, Brufani C, Russo B, Fintini D, Migliaccio A, Pecorelli L, et al. Abnormal glucose tolerance in children with cystic fibrosis: the predictive role of continuous glucose monitoring system. Eur J Endocrinol 2010; 162: 705-10.
Schmid K, Fink K, Holl RW, Hebestreit H, Ballmann M. Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. J Cist Fibros 2014; 13: 80-5.
Sulli N, Bertasi S, Zullo S, Shasaj B. Use of continuous subcutaneous insulin infusion in patients with cystic fibrosis related diabetes: Three case reports. J Cyst Fibros 2007; 6: 237-40.
Bellin MD, Laguna T, Leschyshyn J, Regelmann W, Dunitz J, Billings JA, Moran A. Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study. Pediatric Diabetes 2013: 14: 417–421.
Aris RM, Merkel PA, Bachrach LK, Borowitz DS, Boyle MP, Elkin SL, et al. Consensus statement: guide to bone health and disease in cystic fibrosis. J Clin Endocrinol Metab 2005; 90: 1888-96.
Conway SP, Morton AM, Oldroyd B, Truscott JG, White H, Smith AH, Haigh I. Osteoporosis and osteopenia in adults and adolescents with cystic fibrosis: prevalence and associated factors. Thorax 2000; 55:798-804.
Haworth CS, Selby PL, Webb AK, Dodd ME, Musson H, Niven R McL, et al. Low bone mineral density in adults with cystic fibrosis. Thorax 1999; 54: 961-7.
King SJ, Topliss DJ, Kotsimbos T, Nyulasi IB, Bailey M, Ebeling PR, Wilson JW. Reduced bone density in cystic fibrosis: DF508 mutation is an independent risk factor: Eur Respir J 2005; 25: 54-61.
Sheikh S, Gemma S, Patel A. Factors associated with low bone mineral density in patients with cystic fibrosis. J Bone Miner Metab 2014 Mar 16. [Epub ahead of print]
Aris RM, Stephens AR, Ontjes DA, Blackwood AD, Lark RK, Hensler MB, et al. Adverse alterations in bone metabolism are associated with lung infection in adults with cystic fibrosis. Am J Respir Crit Care Med 2000; 162:1674-8.
Aris RM, Renner JB, Winders AD, Buell HE, Riggs DB, Lester GE, Ontjes DA. Increased rate of fractures and severe kyphosis: sequelae of living into adulthood with cystic fibrosis. Ann Intern Med 1998; 128:186-93.
Gore AP, Kwon SH, Stenbit AE. A roadmap to the brittle bones of cystic fibrosis. J Osteoporos 2010; 16;2011: 926045.
Haworth CS, Selby PL, Adams JE, Mawer EB, Horrocks AW, Webb AK. Effect of intravenuous pamidronate on bone mineral density in adults with cystic fibrosis. Thorax 2001; 56: 314-6.
Aris RM, Lester GE, Caminiti M, Blackwood AD, Hensler M, Lark RK, et al. Efficacy of alendronate in adults with cystic fibrosis with low bone density. Am J Resp Crit Care Med 2004; 169: 77-82.
Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM. The effects of parathyroid hormone, alendronate or both in men with osteoporosis. N Engl J Med 2003; 349: 1216-26.
Horwitz MJ, Tedesco MB, Sereika SM, Garcia-Ocaña A, Bisello A, Hollis BW, Gundberg C, Stewart AF. Safety and tolerability of subcutaneous PTHrP (1-36) in healthy human volunteers: a dose escalation study. Osteoporosis Int 2006; 17: 225-30.
Cummings SR, Martin JS, McClung MR. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361: 756-65.
Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2011; 26: 19-26.
Eddleston A, Marenzna M, Moore AR, Stephens P, Muzylak M, Marshall D, et al. A short treatment with antibody to sclerostin can inhibit bone loss in an ongoing model of colitis. J Bone Miner Res 2009; 24: 1662-71.
De Benedetti F, Meazza C, Martini A. Role of interleukin-6 in growth failure: an animal model. Hormon Res 2002; 58 Suppl 1: 24-7.
Street ME, Spaggiari C, Volta C, Ziveri MA, Viani I, et al. The IGF system and cytokine interactions and realtionships with longitudinal growth in prepubertal patients with cysitis fibrosis. Clin Endocrinol 2009; 70: 593-8.
Guo Y, Su M, McNutt MA, Gu J. Expression and Distribution of Cystic Fibrosis Transmembrane Conductance Regulator in Neurons of the Human Brain. Journal of Histochemistry & Cytochemistry 2009; 57: 1113–20.
Rogan M, Reznikov L, Pezzulo A, et al. Pigs and humans with cystic fibrosis have reduced IGF1 levels at birth. PNAS 2010;107:20571-5.
Phung OJ, Coleman CI, Baker EL, Scholle JM, Girotto JE, Makanji SS, et al. Recombinant human growth hormone in the treatment of patients with cystic fibrosis. Pediatrics 2010; 126: e1211-25.
Stalvey MS, Anbar RD, Konstan MW, Jakobs JR, Bakker B, Lippe B, et al. A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis. Pediatr Pulmonol 2012; 47:252-63.
Bucuvalas JC, Chernausek SD, Alfaro MP, Krug SK, Ritschel W, Wilmott RW. Effect of insulin-like growth factor-1 treatment in children with cystic fibrosis. J Pediatr Gastroenterol Nutr 2001; 33: 576-81.
Haupt ME, Kim EE, Prestridge AL. Successful prolonged use of recombinant human insulin-like growth factor-1 in child with cystis fibrosis. Pediatr Pulmonol 2011; 46: 1137-41.
Sharma R, Florea VG, Bolger AP, Doehner W, Florea ND, Coats AJ, et al. Wasting as an independent predictor of mortality in patients with cystic fibrosis. Thorax 2001;56:746-50.
Graff GR, McNamara J, Royall J, Caras S, Forssmann K. Safety and tolerability of a new formulation of pancrelipase delayed-release capsules (CREON) in children under seven years of age with exocrine pancreatic insufficiency due to cystic fibrosis: an open-label, multicentre, single-treatment-arm study. Clin Drug Investig 2010;30:351-64.
Borowitz D, Stevens C, Brettman LR, Campion M, Wilschanski M, Thompson H; Liprotamase 767 Study Group. Liprotamase long-term safety and support of nutritional status in pancreatic-insufficient cystic fibrosis.J Pediatr Gastroenterol Nutr 2012;54:248-57.
Blondeau K, Pauwels A, Dupont Lj, Mertens V, Proesmans M, Orel R, et al. Characteristics of gastroesophageal reflux and potential risk of gastric content aspiration in children with cystic fibrosis. J Pediatr Gastroenterol Nutr 2010;50:161-6.
Colombo C, Ellemunter H, Houwen R, Munck A, Taylor C, Wilschanski M; ECFS. Guidelines for the diagnosis and management of distal intestinal obstruction syndrome in cystic fibrosis patients. J Cyst Fibros 2011;10 Suppl 2:S24-8.
Munck A, Pesle A, Cunin-Roy C, Gerardin M, Ignace I, Delaisi B, Wood C. Recurrent abdominal pain in children with cystic fibrosis: a pilot prospective longitudinal evaluation of characteristics and management. J Cyst Fibros 2012;11:46-8.
Debray D, Kelly D, Houwen R, Strandvik B, Colombo C. Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease. J Cyst Fibros 2011;10 Suppl 2:S29-36.
Borinc BA, Brecelj J, Bratanič N, Homan M, Homšak M, Jenko K, et al. Smernice za obravnavo otrok s cistično fibrozo. Zdrav Vestn 2008; 77:679-92.
Maqbool A, Stallings VA. Update on fat-soluble vitamins in cystic fibrosis. Curr Opin Pulm Med 2008;14:574-81.
McCowen KC, Bistrian BR. Essential fatty acids and their derivatives. Curr Opin Gastroenterol 2005; 21: 207-15.
Dodge JA, Lewis PA, Stanton M, Wilsher J. Cystic fibrosis mortality and survival in the UK: 1947-2003. Eur Respir J 2007; 29:522-6.
Flume PA, Anderson DL, Hardy KK, Gray S. Transition programs in cystic fibrosis centers: perceptions of pediatric and adult program directors. Pediatr Pulmonol 2001; 31:443-450
Grenet D, Bonnel AS, Dautricourt C, De Miranda S, Foucaud P, Stern M. Transition of adolescents and young adults from pediatric to adult care. Arch Pediatr 2012; Suppl 1: S33-5
Tuchman LK, Schwartz LA, Sawicki GS, Britto MT. Cystic fibrosis and transition to adult medical care. Pediatrics 2010;125:566-73.
McLaughlin SE, Diener-West M, Indurkhya A, Rubin H, Heckmann R, Boyle MP. Improving transition from pediatric to adult cystic fibrosis care: lessons from a national survey of current practices. Pediatrics 2008;121:1160-6.
Towns SJ, Bell SC. Transition of adolescents with cystic fibrosis from paediatric to adult care. Clin Respir J 2011; 5:64-75.
Chaudhry SR, Keaton M, Nasr SZ. Evaluation of a cystic fibrosis transition program from pediatric to adult care. Pediatr Pulmonol 2013; 48:658-65.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
